- Home
- NRIX
as 11-01-2025 4:27am EST
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.
| Founded: | 2009 | Country: | United States |
| Employees: | N/A | City: | SAN FRANCISCO |
| Market Cap: | 750.4M | IPO Year: | 2020 |
| Target Price: | $26.29 | AVG Volume (30 days): | 1.9M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 14 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.97 | EPS Growth: | N/A |
| 52 Week Low/High: | $8.18 - $29.56 | Next Earning Date: | 10-09-2025 |
| Revenue: | $83,687,000 | Revenue Growth: | 48.32% |
| Revenue Growth (this year): | 58.48% | Revenue Growth (next year): | -36.42% |
Stock Insider Trading Activity of Nurix Therapeutics Inc. Common stock (NRIX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| van Houte Hans | NRIX | Chief Financial Officer | Oct 30 '25 | Sell | $12.80 | 3,130 | $40,053.67 | 43,876 | |
| Hansen Gwenn | NRIX | Chief Scientific Officer | Oct 30 '25 | Sell | $12.80 | 4,087 | $52,300.11 | 76,751 | |
| Ring Christine | NRIX | Chief Legal Officer | Oct 30 '25 | Sell | $12.80 | 3,644 | $46,631.17 | 50,897 |
Latest Nurix Therapeutics Inc. Common stock News
NRIX Breaking Stock News: Dive into NRIX Ticker-Specific Updates for Smart Investing
GlobeNewswire
4 days ago
Nurix Therapeutics to Participate in Upcoming Investor Conferences
MT Newswires
7 days ago
Nurix Therapeutics Closes $250 Million Underwritten Public Stock Offering
GlobeNewswire
7 days ago
Nurix Therapeutics Announces Closing of $250.0 Million Registered Offering of Common Stock
GlobeNewswire
5 months ago
Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MT Newswires
5 months ago
RBC Raises Price Target on Nurix Therapeutics to $28 From $27, Keeps Outperform, Speculative Risk
GlobeNewswire
5 months ago
Nurix Therapeutics Presents Updated Positive Data Demonstrating Durable, Deepening Responses in Ongoing Clinical Trial of Bexobrutideg (NX-5948) Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Waldenström Macroglobulinemia (WM)
GlobeNewswire
5 months ago
Nurix Therapeutics to Host a Webcast Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of Bexobrutideg (NX-5948) Being Presented at the 30th European Hematology Association Congress (EHA2025)
Zacks
5 months ago
Nurix Therapeutics (NRIX) Moves 14.2% Higher: Will This Strength Last?
Compare NRIX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NRIX Nurix Therapeutics Inc. Common stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.